Cyclin-binding Motifs Are Essential for the Function of P21CIP1
Overview
Authors
Affiliations
The cyclin-dependent kinase (Cdk) inhibitor p21 is induced by the tumor suppressor p53 and is required for the G1-S block in cells with DNA damage. We report that there are two copies of a cyclin-binding motif in p21, Cy1 and Cy2, which interact with the cyclins independently of Cdk2. The cyclin-binding motifs of p21 are required for optimum inhibition of cyclin-Cdk kinases in vitro and for growth suppression in vivo. Peptides containing only the Cy1 or Cy2 motif partially inhibit cyclin-Cdk kinase activity in vitro and DNA replication in Xenopus egg extracts. A monoclonal antibody which recognizes the Cy1 site of p21 specifically disrupts the association of p21 with cyclin E-Cdk2 and with cyclin D1-Cdk4 in cell extracts. Taken together, these observations suggest that the cyclin-binding motif of p21 is important for kinase inhibition and for formation of p21-cyclin-Cdk complexes in the cell. Finally, we show that the cyclin-Cdk complex is partially active if associated with only the cyclin-binding motif of p21, providing an explanation for how p21 is found associated with active cyclin-Cdk complexes in vivo. The Cy sequences may be general motifs used by Cdk inhibitors or substrates to interact with the cyclin in a cyclin-Cdk complex.
The Emerging Role of p21 in Diabetes and Related Metabolic Disorders.
Elmitwalli O, Darwish R, Al-Jabery L, Algahiny A, Roy S, Butler A Int J Mol Sci. 2024; 25(23).
PMID: 39684919 PMC: 11641910. DOI: 10.3390/ijms252313209.
Riutin M, Erez P, Adler J, Biran A, Myers N, Shaul Y Cells. 2024; 13(19.
PMID: 39404432 PMC: 11476297. DOI: 10.3390/cells13191670.
Senescence and SASP Are Potential Therapeutic Targets for Ischemic Stroke.
Ouvrier B, Ismael S, Bix G Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543098 PMC: 10973994. DOI: 10.3390/ph17030312.
L.: Ethnobotany, Phytochemistry, Phytonanotechnology, and Commercial Application.
Kumar S, Kumar S, Vishnoi V, Kumar P, Maheshwari D Curr Pharm Biotechnol. 2023; 25(7):838-859.
PMID: 37861013 DOI: 10.2174/0113892010262937230919100024.
Emerging approaches to CDK inhibitor development, a structural perspective.
Hope I, Endicott J, Watt J RSC Chem Biol. 2023; 4(2):146-164.
PMID: 36794018 PMC: 9906319. DOI: 10.1039/d2cb00201a.